

1 **Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in people aged**  
2 **at least 75 years in the UK vaccination programme, during the Spring-Summer**  
3 **(monovalent vaccine) and Autumn-Winter 2022 (bivalent vaccine) booster campaigns: a**  
4 **prospective test negative case-control study**

5 Dr Anastasia Chatzilena PhD<sup>†</sup>, Engineering Mathematics, University of Bristol, Bristol, UK

6 Dr Catherine Hyams PhD<sup>†</sup>, Population Health Sciences, University of Bristol, Bristol, UK

7 Dr Rob Challen PhD, Engineering Mathematics, University of Bristol, Bristol, UK

8 Dr Robin Marlow PhD, Population Health Sciences, University of Bristol, Bristol, UK

9 Ms Jade King MSc, Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, UK

10 Mr David Adegbite BSc, Bristol Vaccine Centre, Population Health Sciences, University of  
11 Bristol, Bristol, UK

12 Ms Jane Kinney BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol,  
13 Bristol, UK

14 Ms Madeleine Clout BSc, Bristol Vaccine Centre, Population Health Sciences, University of  
15 Bristol, Bristol, UK

16 Prof Nick Maskell MD, Academic Respiratory Unit, University of Bristol, Southmead Hospital,  
17 Bristol, UK

18 Dr Jennifer Oliver PhD, Bristol Vaccine Centre, Population Health Sciences, University of  
19 Bristol, Bristol, UK

20 Professor Adam Finn PhD<sup>†</sup>, Bristol Vaccine Centre, Cellular and Molecular Medicine and  
21 Population Health Sciences, University of Bristol, Bristol, UK

22 Dr Leon Danon PhD<sup>†</sup>, Engineering Mathematics, University of Bristol, Bristol, UK  
23 (Corresponding Author)

24 The Avon CAP Research Group

25 <sup>†</sup> These authors contributed equally, and should be considered co-first or last authors

26

27 Corresponding Author: Leon Danon, PhD  
28 Engineering Mathematics, University of Bristol  
29 University Walk  
30 Bristol BS8 1TW  
31 United Kingdom  
32 +44(0)117 455 7828  
33 l.danon@bristol.ac.uk  
34  
35  
36  
37 Keywords: COVID-19, SARS-CoV-2, respiratory infection, vaccination

38 **ABSTRACT (245/250 words)**

39 **Background**

40 Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations  
41 against SARS-CoV-2 infection is an urgent public health priority. A precise analysis of the rVE  
42 of monovalent and bivalent boosters given during the 2022 Spring-Summer and Autumn-Winter  
43 campaigns, respectively, in a defined population has not been reported.

44 **Aim**

45 We therefore assessed rVE against hospitalisation for the Spring-Summer (fourth vs third  
46 monovalent mRNA vaccine doses) and Autumn-Winter (fifth BA.1/ancestral bivalent vs fourth  
47 monovalent mRNA vaccine dose) boosters.

48 **Methods**

49 A prospective single-centre test-negative design case-control study of  $\geq 75$  year-olds hospitalised  
50 with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling  
51 for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence,  
52 vaccine brand and time between baseline dose and hospitalisation.

53 **Results**

54 682 controls and 182 cases were included in the Spring-Summer booster analysis; 572 controls  
55 and 152 cases for the Autumn-Winter booster analysis. A monovalent mRNA COVID-19  
56 vaccine as fourth dose showed rVE 46.6% (95% confidence interval [CI] 13.9-67.1) versus those

57 not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had rVE 46.7% (95%CI  
58 18-65.1), compared to a fourth monovalent mRNA COVID-19 vaccine dose.

## 59 **Conclusions**

60 Both fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses  
61 demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offer similar  
62 protection against hospitalisation with Omicron infection to monovalent mRNA boosters given  
63 earlier in the year. These findings support immunisation programmes in several European  
64 countries that advised the use of BA.1/ancestral bivalent booster doses.

## 65 INTRODUCTION

66 Following the emergence of wild-type SARS-CoV-2 and circulation of antigenically distinct  
67 variants, large-scale vaccination programmes were implemented to reduce overall COVID-19  
68 morbidity and mortality. In the UK, several COVID-19 vaccines received rapid regulatory  
69 authorisation: the vaccines used initially were the monovalent mRNA vaccine BNT162b2  
70 (Cominarty®) and the ChAdOx1 (Vaxzevria®) replication-deficient simian adenovirus vector  
71 vaccine, with mRNA-1273 (Spikevax®) vaccine incorporated a few months later. These three  
72 COVID-19 vaccines were used in the primary campaign in the UK which began in December  
73 2020, using initially an extended interval between first and second doses equal to 12 weeks, to  
74 prioritise first dose administration. The mRNA vaccines were offered as boosters 6-months after  
75 completion of the primary course, from September 2021 for adults aged  $\geq 50$  years (y) and those  
76 in clinical risk groups, extending to all adults in November 2021. A fourth dose of an mRNA  
77 vaccine was offered from March 2022 and prioritised the most vulnerable: all adults aged  $\geq 75$  y,  
78 and those in clinical risk groups[1]. A third priming vaccine dose had already been offered to  
79 immunosuppressed individuals, so that for them, the autumn 2021 and spring 2022 boosters were  
80 generally their fourth and fifth doses, respectively. The COV-Boost study indicated that a fourth-  
81 dose COVID-19 mRNA vaccination boosts immune responses[2], and an observational study  
82 showed three or four-dose vaccine effectiveness (VE) against hospitalisation of 60.9-62.1%  
83 against BA.4 or BA.5 variants which emerged during spring 2022 and 50.1% against BA.2 when  
84 compared to two-doses received  $\geq 25$  weeks earlier[3]. These initial COVID-19 vaccines were  
85 developed against wild-type virus and provided significant protection against infection,  
86 hospitalisation, severe disease and death[4–8]. However, VE has been eroded progressively both

87 by waning of immune-protection over time and emergence of SARS-CoV-2 variants of concern  
88 (VOC) (Alpha, Delta, Omicron) which show immune escape, [9–12].

89

90 In summer 2022, the UK Medicines & Healthcare products Regulatory Agency (MHRA)  
91 approved two new bivalent booster vaccines which were developed in response to concerns  
92 about such viral evolution and escape. The Moderna bivalent vaccine (Spikevax® bivalent  
93 Original/Omicron) was approved on 15th August 2022, followed quickly by Pfizer/BioNTech  
94 bivalent vaccine (Comirnaty® Original/Omicron BA.1) approval on 3rd September 2022[13,14]  
95 and they were distributed during autumn 2022, being the fifth dose offered in the UK. The  
96 Moderna vaccine contains 25mcg of mRNA coding for the spike protein of the ancestral strain  
97 and 25mcg of mRNA against Omicron (BA.1) and the Pfizer BioNTech vaccine contains 15mcg  
98 of mRNA directed against the ancestral strain and 15mcg of mRNA against Omicron (BA.1).  
99 Early immunogenicity studies suggest bivalent mRNA boosters induce similar or higher  
100 neutralising antibody levels against Omicron sub-variants and other VOCs compared to  
101 monovalent mRNA boosters[15–19].

102

103 SARS-CoV-2 infection incidence remains high[20], whilst determining whether patients who  
104 test SARS-CoV-2 positive have COVID-19 has become increasingly challenging using studies  
105 relying on data linkage methodology. Additionally, comparison between vaccinated individuals  
106 and those who have not received any COVID-19 vaccine dose cannot be performed, as 78.2% of  
107 the adult population in the UK have received at least 2 doses or had prior exposure to SARS-  
108 CoV-2: thus even unvaccinated individuals have some immunity to SARS-CoV-2. There remains

109 limited evidence[10,15,21] of bivalent vaccines' clinical effectiveness when compared to  
110 monovalent formulations because the different vaccine rollout timings make a direct comparison  
111 of the vaccines impossible. Acknowledging this constraint, we undertook a test-negative design  
112 (TND) case control study comparing SARS-CoV-2 positive and negative acute lower respiratory  
113 tract disease (aLRTD) patients, implementing two separate analyses to assess the protection  
114 against SARS-CoV-2 hospitalisation provided by an additional monovalent or BA.1/ancestral  
115 bivalent mRNA vaccine dose relative to those who had not received the respective doses,  
116 focusing on  $\geq 75$ y olds who were the main target group in the spring 2022 booster programme.  
117 Given the different rollout timings of the two vaccine formulations, the analyses refer to two  
118 distinct study time periods with different subvariants circulating.

## 119 **METHODS**

### 120 **Study design and conduct**

121 We estimated the relative vaccine effectiveness (rVE) of monovalent and bivalent mRNA  
122 vaccines against hospitalisation in Bristol, within the study population consisting of adults  
123 admitted to North Bristol and University Hospitals Bristol and Weston NHS Trusts [AvonCAP:  
124 ISRCTN17354061] between 4th April 2022 and 30th July 2022 (the period following the  
125 initiation of distribution of fourth dose of monovalent mRNA vaccines), and between 21st  
126 September 2022 and 23rd January 2023 (the period following the initiation of distribution of  
127 bivalent mRNA vaccines) inclusive. During the first study period BA.4, BA.2 and BA.5 were the  
128 main Omicron sub-lineages identified in COVID-19 cases in England, while the dominant sub-  
129 lineages identified during the second study period were BA.5, BA.4.6, BQ.1, CH1.1, XBB  
130 recombinant lineage and its mutation XBB.1.5 (Supplementary Data S2) [22]. The study  
131 population consisted of patients with signs/symptoms of respiratory infection, aged  $\geq 18$ y at the  
132 time of hospitalisation[23]. Study eligible cases and controls eligible were identified from the  
133 medical admission list, and data were collected from medical records using REDCap  
134 software[24]. All data collection was undertaken by individuals not involved in analysis and  
135 blinded to results, following the same procedures for both cases and controls. Vaccination  
136 records for every study participant were obtained from linked hospital and GP records, including  
137 vaccine brand and date of administration with data collection performed by individuals blinded  
138 to participants' SARS-CoV-2 test results[25].

139

140



141

142 **Case definition and exclusions**

143 We included patients with  $\geq 2$  signs of acute respiratory disease (cough, fever, dyspnoea,  
144 tachypnoea, increased/discoloured sputum expectoration, pleurisy, clinical or radiological  
145 findings suggestive of acute disease) or a confirmed clinical/radiological diagnosis of  
146 aLRTD[25]. Patients hospitalised with aLRTD and positive admission SARS-CoV-2 test using  
147 the UK Health Security Agency (UKHSA) diagnostic assay in use at the time were classified as  
148 cases; those with aLRTD and negative SARS-CoV-2 result were classified as controls. Eligible  
149 controls could have multiple hospitalisations, provided subsequent admissions were  $>7$  days  
150 following previous discharge. We included only the first COVID-19 admission for each case.

151

152 We excluded patients whose admission date was  $>10$  days after symptom onset date (to avoid  
153 including potentially false negative admission SARS-CoV-2 tests), and those with a confirmed  
154 previous SARS-CoV-2 infection based on any positive test result that could be found in local  
155 and/or national clinical care record database, including linkage through the UKHSA national  
156 testing system. Patients who had received 2 vaccine doses or fewer at the time of admission were  
157 also excluded (Supplementary Data S1).

158

159 In order to make a side-by-side evaluation of the effectiveness of the different booster vaccine  
160 formulations, we restricted both analyses to individuals aged  $\geq 75$ y, since the Joint Committee on  
161 Vaccination and Immunisation (JCVI) advised targeting COVID-19 booster vaccines during

162 spring-summer towards those at highest risk of severe disease; those aged  $\geq 75$ y and residents in  
163 long-term care facilities (LTCFs)[1], while in Autumn-Winter 2022 the offer was extended,  
164 including those aged  $\geq 50$ y and frontline health and social care workers [26]. Therefore, patients  
165  $< 75$ y were excluded from analyses.

166

## 167 **Exposure definition**

168 This analysis aims to measure the protection offered by an additional dose of monovalent  
169 (Original ‘wild-type’ mRNA vaccine, Pfizer-BioNTech [Comirnaty®] or Moderna [Spikevax®])  
170 and bivalent (Original ‘wild-type’/Omicron BA.1 mRNA vaccine, Pfizer-BioNTech  
171 [Comirnaty®] or Moderna [Spikevax®]) vaccine within 3 months after vaccination, each  
172 compared with those who had not received the respective boosters, side by side, during SARS-  
173 CoV-2 Omicron variant dominance. The Spring-Summer monovalent booster analysis  
174 (admissions 04/04/22-30/07/22) compares the fourth dose of monovalent given as a booster  
175 (21/03/22-07/08/22) in the UK, to the third dose of monovalent vaccine during Autumn-Winter  
176 2021 (16/09/21-14/02/22). By the end of this study period, the vaccine uptake in the UK in the  
177 over 75s was 74.3% for spring 2022 booster and 93.5% for 3 doses (cf. median vaccine uptake of  
178 13.6% and 84.2% respectively in EU/EEA countries in over 60 year olds, based on available data  
179 [27]). The Autumn-Winter bivalent booster analysis (admissions 21/09/22-23/01/23) compares  
180 the fifth dose of vaccine, with the bivalent formulation given as a booster (07/09/22-12/02/23) to  
181 the fourth dose of monovalent vaccine in Spring-Summer 2022 (21/03/22-07/08/22). The vaccine  
182 uptake in individuals aged  $\geq 75$ y by the end of this study period was 83.5% for autumn 2022

183 booster and 74.9% for spring 2022 booster (cf. median vaccine uptake of 2.2% and 35.1%  
184 respectively in EU/EEA countries in over 60 year olds based on available data [27]).

185

186 For the Spring-Summer monovalent booster analysis, individuals were defined as boosted with a  
187 monovalent vaccine if they had received three doses of any monovalent vaccine combination and  
188 a fourth dose of monovalent vaccine during the Spring-Summer 2022 vaccination programme,  
189 and no more than three months prior to their admission, and as not fully boosted only if they had  
190 received two doses of any vaccine combination followed by a third dose of monovalent vaccine  
191 during Autumn-Winter 2021. For the Autumn-Winter bivalent booster analysis, individuals were  
192 defined as boosted with a BA.1/ancestral bivalent vaccine if they had received four doses of any  
193 vaccine combination plus a fifth bivalent dose during Spring-Summer 2022 vaccination  
194 programme and no more than three months prior to their admission, and as not fully boosted if  
195 they had received three doses of any vaccine combination plus a fourth monovalent dose during  
196 Autumn-Winter 2022. In both analyses, we define those having received the most recent dose  
197 with >7 days having elapsed between the vaccine and symptom onset as immunised  
198 (Supplementary Data S1).

199

200 Individuals who received a third vaccine dose in Autumn-Winter 2021, a fourth dose in Spring-  
201 Summer 2022 and a fifth dose in Autumn-Winter 2022, are those who had received two doses as  
202 the primary vaccination regimen before and during Spring-Summer 2021. However, individuals  
203 with severe immunosuppression around the time of their first or second vaccine doses were  
204 offered an additional primary dose (third dose) before any booster doses. As a result, they were

205 offered a fourth vaccine dose in Autumn-Winter 2021, a fifth dose in Spring-Summer 2022 and a  
206 sixth dose in Autumn-Winter 2022 (Figure 1, Supplementary Data S2). Since this population  
207 almost exclusively comprised of immunosuppressed individuals we perform additional  
208 sensitivity analyses including those individuals who had received three doses as their primary  
209 vaccination regimen in both comparisons.

210

## 211 **Outcomes**

212 We assessed the additional protection provided by a fourth dose of mRNA monovalent vaccine  
213 and a fifth dose of BA.1/ancestral bivalent vaccine as boosters against the primary endpoint of  
214 hospital admission with a positive admission SARS-CoV-2 test and either a clinical or  
215 radiological aLRTD diagnosis or aLRTD signs/symptoms compared to that provided by three or  
216 four doses of the monovalent formulations of the vaccines, respectively.

217

## 218 **Statistical Analysis**

219 Demographic, clinical characteristics and other factors that may affect the exposure (vaccination  
220 status) or outcome (hospital admission) were compared between cases and controls for both  
221 comparisons, between monovalent vaccine boosted and not fully boosted, and between boosted  
222 with a bivalent vaccine and not fully boosted, using Fisher exact tests (categorical variables),  
223 two-sided Kolmogorov-Smirnov tests (continuous variables) and Wilcoxon rank-sum tests (score  
224 variables).

225

226 Under TND assumptions, we estimate the odds ratio of testing SARS-CoV-2 positive among  
227 patients boosted with a monovalent vaccine versus those not fully boosted (rOR) and define rVE  
228 as  $(1-rOR) \times 100$ . Similarly, we estimated rVE of bivalent booster, comparing the odds of testing  
229 positive for SARS-CoV-2 among patients boosted with a bivalent vaccine versus those not fully  
230 boosted. This was done using univariable logistic regression (Univariable Logistic Regression  
231 Model). Differences in the timing of third/fourth dose and rollout timings of different vaccine  
232 brands could introduce unobserved biases, confounding results in both comparisons. To mitigate  
233 these, we performed multivariable logistic regression analyses adjusting for time between  
234 baseline vaccine dose (third dose for the Spring-Summer monovalent booster, and fourth dose  
235 for the Autumn-Winter bivalent booster analysis) and admission (in days), vaccine brand [binary  
236 variable], age, sex, Index of Multiple Deprivations (IMD) decile rank and Charlson comorbidity  
237 index (CCI) [continuous variable], LTCF residency status, presence of pre-existing respiratory  
238 disease, and community SARS-CoV-2 prevalence lagged by time interval between infection and  
239 hospitalisation, assumed to be 8-days (Multivariable Logistic Regression Model).

240

241 We also conducted sensitivity analyses, matching cases and controls using propensity score  
242 balancing using logistic regression to define propensity score, and nearest neighbour matching.  
243 Matching variables included age, sex, CCI and IMD, LTCF residency status and presence of pre-  
244 existing respiratory disease, and likelihood of vaccine receipt (Matched Conditional Logistic  
245 Regression Model). Matching by elapsed time since baseline vaccine dose/brand was not  
246 performed to avoid introducing bias[28]. Time since baseline vaccine dose/ brand is affected by

247 dose of last vaccine received; each booster was deployed  $\geq 4$  months after the previous COVID-  
248 19 booster programme (Figure 1), with different programmes using different proportions of each  
249 vaccine brand. As additional sensitivity analysis, we included individuals who had received three  
250 doses as primary vaccination regimen, adjusting for the number of primary doses [binary  
251 variable], using the same methods for both comparisons.

252

253 Statistical analyses were performed with R v4.0.2. Missing data were limited to the IMD variable  
254 and accounted for  $< 1\%$ ; no imputation was performed; all analyses only included participants  
255 with complete data. Statistical significance was defined using a 2-sided significance level of  
256  $\alpha = 0.05$ .

257

## 258 **Ethics and permissions**

259 The Health Research Authority Research Ethics Committee (East of England, Essex),  
260 REC20/EE/0157 approved this study, including using Section 251 of the 2006 NHS Act under  
261 Confidentiality Advisory Group authorisation.

262

## 263 **Role of the funding source**

264 This study was conducted as a collaboration between The University of Bristol (study sponsor)  
265 and Pfizer (study funder). The study funder did not undertake any data collection, data analysis  
266 or manuscript preparation.

## 267 RESULTS

268 During the periods evaluated, 9,868 adult aLRTD hospitalisations occurred in Bristol, UK, while  
269 the Omicron variant was dominant[22,29,30]. In the Spring-Summer booster, 864 admissions of  
270  $\geq 75$ y old patients hospitalised with SARS-CoV-2 aLRTD were eligible for this analysis: median  
271 patient age was 85y (IQR 80-89), 403 individuals (46%) were male, median CCI was 5 (IQR 4-  
272 6) with no significant differences in patient age and sex between SARS-CoV-2 positive and  
273 negative aLRTD, while there was a statistically significant difference in their ethnicity, LTCF  
274 residency status, smoking and presence of pre-existing respiratory disease and chronic  
275 obstructive pulmonary disease (Figure 1, Table 1). In the Autumn-Winter booster, 884  
276 admissions of  $\geq 75$ y old patients were eligible with no significant differences in age, sex and  
277 LTCF residency status between SARS-CoV-2 positive and negative aLRTD, while differences in  
278 ethnicity, smoking and dementia status were statistically significant (Figure 1, Table 2). In both  
279 comparisons, there were no significant differences in patient demographics and health status  
280 between vaccination groups (Supplementary Data S3, S4).

281

282 In the Spring-Summer booster analysis, of the 182 SARS-CoV-2 cases, 78 (43%) received a  
283 fourth monovalent vaccine dose and 104 (57%) received a third monovalent vaccine dose, while  
284 413 of 682 controls (61%) received a fourth monovalent vaccine dose and 269 (39%) received a  
285 third monovalent vaccine dose. All those vaccinated with a fourth monovalent dose were  
286 hospitalised  $\leq 3$  months after their vaccination and 98% of those who had received only 3 doses  
287 were hospitalised  $> 3$  months after their vaccination (Supplementary Data S3). The unadjusted  
288 rVE was 51.2% (95%CI 32.1-65) and after adjustment, rVE was 46.6% (95%CI 13.9-67.1).

289 Matched conditional logistic regression rVE was 52% (95%CI 20·9-70·9) (Table 3). Sensitivity  
290 analysis including individuals with three doses as primary vaccination regimen (who make up  
291 8.5% of cases and 5.8% of controls) resulted in lower rVE estimates compared with results from  
292 the main analysis (Table 3, Supplementary Data S5, S6, S9).

293

294 In the Autumn-Winter booster analysis, of the 152 SARS-CoV-2 cases, 100 (66%) received a  
295 fifth BA.1/ancestral bivalent vaccine dose and 52 (34%) received a fourth monovalent vaccine  
296 dose, while 572 of 732 (78%) controls received a fifth bivalent vaccine dose and 160 (22%)  
297 received a fourth monovalent vaccine dose. All those vaccinated with a fifth BA.1/ancestral  
298 bivalent vaccine dose were hospitalised  $\leq 3$  months after their vaccination and 97% of those who  
299 had received only 3 doses were hospitalised  $> 3$  months after their vaccination (Supplementary  
300 Data S4). The unadjusted rVE was 46·2% (95%CI 21·1-63) and after adjustment, rVE was  
301 46·7% (95%CI 18-65·1). Matched conditional logistic regression rVE was 48·8% (95%CI 19·8-  
302 67·3) (Table 4). The inclusion of individuals with three doses as primary vaccination regimen  
303 (who make up 3.8% of cases and 6.9% of controls) produced estimates comparable with results  
304 from the main analysis (Table 4, Supplementary Data S7, S8, S10).



## 305 **DISCUSSION**

306 In this analysis, we consider the public health implications of monovalent and BA.1/ancestral  
307 bivalent vaccine implementation, focusing on people aged  $\geq 75$ y; a high-risk group which was a  
308 primary target for the UK vaccination programme. Although COVID-19 vaccines have been  
309 shown to be effective against severe COVID-19 disease[4,31,32], it has not been possible to  
310 compare the effectiveness of monovalent boosters directly with BA.1/ancestral bivalent booster  
311 doses of mRNA COVID-19 vaccines in defined populations, because bivalent formulations  
312 rapidly and entirely replaced monovalent formulations in the most recent booster programmes. In  
313 this ongoing prospective study, we undertake a sequential sub-analysis of the two vaccines given  
314 as boosters during two booster programmes in the same calendar year, providing evidence that  
315 monovalent vaccine (Original ‘wild-type’ Comirnaty® and Spikevax®) and BA.1/ancestral  
316 mRNA bivalent vaccine (Original ‘wild-type’/Omicron BA.1 Cominarty® and SpikeVax®)  
317 within three months after vaccination provided similar additional protection compared to that  
318 afforded by waned previous doses against hospitalisation from Omicron SARS-CoV-2 sub-  
319 variants in older individuals, given unknown effects of the different subvariant circulating during  
320 the distribution of the two vaccine formulations (Supplementary Data 2 C).

321

322 Specifically, we estimated that a fourth monovalent mRNA vaccine dose within three months  
323 after vaccination, was associated with a 46·6% (95%CI 13·9-67·1) additional protection against  
324 hospitalisation compared to waned three doses, in individuals  $\geq 75$ y, during Omicron BA.2,  
325 BA.4, BA.5 lineage dominance. Within three months of receiving a fifth bivalent mRNA vaccine  
326 dose, it is estimated to provide 46·7% (95%CI 18-65·1) additional protection against

327 hospitalisation compared to waned four doses, in the same  $\geq 75$ y age group, even when assessed  
328 during a period when heterologous variants were circulating since BA.5, BA.4.6, BQ.1 and  
329 CH1.1 lineages, the XBB recombinant lineage and its mutation XBB.1.5 accounted for most of  
330 the identified cases in England (Supplementary Data 2 C) [22].

331

332 Although our results demonstrate that both vaccine formulations combined in these booster  
333 programmes had benefits when used as boosters, we have insufficient case numbers to draw  
334 conclusions about individual vaccine brands or directly compare them. Importantly, this analysis  
335 is restricted to individuals  $\geq 75$ y old, with 97-98% of not fully boosted individuals in our sample  
336 potentially having waned vaccine-induced immunity since they received their last dose more  
337 than 3 months prior to admission (Supplementary Data S2, S3). Given that this study has a short  
338 follow up period after the administration of the two boosters, we cannot provide estimates by  
339 time since vaccination; nonetheless it presents encouraging evidence of similar benefit of  
340 monovalent and bivalent boosters in older adults, up to three months after vaccination. Older  
341 adults are at increased risk of severe disease, and protection may wane faster [33]; older adults  
342 were therefore targeted in the UK Spring-Summer 2022 and Autumn-Winter 2022 COVID-19  
343 booster programmes. Our analysis based on the inclusion of individuals with severely weakened  
344 immune systems who were eligible for three primary doses in our basic comparisons, suggests  
345 that both vaccine formulations may offer some additional protection, however given that they  
346 account for  $< 7\%$  of our sample we have insufficient statistical power to draw firm conclusions.

347

348 Vaccination against SARS-CoV-2 is independently associated with lower COVID-19  
349 severity[4,31,32], and vaccines have been an important disease modifier during the pandemic.  
350 Our estimates suggest that the bivalent boosters provided similar protection as monovalent  
351 boosters in a real-world setting where the landscape of COVID-19 variants is constantly  
352 changing: results concordant with early evidence suggesting neutralising antibody titres induced  
353 against Omicron by a bivalent booster dose were not higher than following a monovalent booster  
354 dose in small studies[16,17]. Our results are concordant with a recent UKHSA analysis[34]  
355 which estimated the incremental protection conferred by a fourth monovalent dose compared to  
356 waned third dose was 58.8% (95%CI 54-63%), while the additional protection of BA.1/ancestral  
357 mRNA bivalent vaccines relative to those with  $\geq 2$  doses and waned protection was 57% (95%CI  
358 48-65%), during the same time period as our analysis.

359

360 Since the study took place over the course of two different time periods, the interpretation of  
361 these sequential analyses of the two vaccine formulations has to take into account the different  
362 variants circulating[22,29,30]. In England, the Omicron variants BA.2, BA.4, BA.5 were the  
363 main circulating variants during the study period of the monovalent booster, and were replaced  
364 by BA.4 and BA.5 descendent sub-lineages(BA.4.6, BQ.1), CH1.1, XBB and XBB.1.5 lineage  
365 during the study period of the BA.1/ancestral bivalent boosters, with BA.5 being the only  
366 subvariant in common. Consequently, in this study, the performance of the BA.1/ancestral  
367 bivalent booster was not evaluated against homologous subvariants but against BA.4/5 which  
368 show further immune escape beyond that observed for BA.1. Currently, there is no evidence that  
369 Omicron BA.4-related sublineages, Omicron BA.5-related sublineages, CH1.1 and XBB  
370 recombinant-related sublineages, which appeared during the study period of the BA.1/ancestral

371 mRNA bivalent boosters, cause more severe disease. The impact of these lineages on the  
372 effectiveness of the BA.1/ancestral mRNA bivalent formulation has not yet been studied in  
373 detail.

374

375 The TND has been described previously, along with its advantages and limitations[12,25,35],  
376 and our analysis has some important additional strengths and limitations. The strength of our  
377 approach is the focus on using real-world data, while accounting for the potential effects of  
378 LTCF residency status, socioeconomic status and comorbidities. By limiting our analysis to  
379 boosted individuals only, our analysis sidesteps the potentially unfair comparisons between  
380 populations that have followed UK COVID-19 vaccine recommendations and unvaccinated  
381 populations that may display other idiosyncratic behaviours. We also utilised symptom onset  
382 date to define illness start time and are able to confirm that there is no difference in time since  
383 vaccination between the case and control groups compared. We, therefore, define illness onset  
384 relative to both vaccination and hospitalisation date accurately, without relying on positive test  
385 date (which may vary widely), eliminating this source of bias or misclassification. All patients  
386 were hospitalised with acute respiratory illness, so these results are unlikely to be subject to  
387 significant bias caused by admission for other causes (i.e., incidental COVID-19 disease). Most  
388 notably, our estimates for the effect of individual vaccines are underpowered, due to small  
389 patient numbers in our cohort during the phases of the UK vaccination programme and study  
390 periods. We are unable to assess additional protection against other markers of disease severity,  
391 such as admission to intensive care or requirement for respiratory support, due to the small  
392 number of eligible admissions in this time period. This analysis does not measure rVE in  
393 individuals who were not hospitalised or were asymptomatic, so we cannot determine protection

394 against asymptomatic disease or transmission. Treatment biases may result in community-based  
395 treatment, death before admission, or patients may otherwise not be referred to hospital. We note  
396 that this cohort, whilst broadly representative of the UK population, was predominantly  
397 Caucasian and the studied vaccines may have different effectiveness in individuals from other  
398 ethnic backgrounds.

399

400 In this prospective study, we provide evidence that autumn BA.1/ancestral mRNA bivalent  
401 COVID-19 boosters offered similar augmentation of protection against Omicron hospitalisation  
402 to that induced by spring monovalent mRNA boosters in 2022. These findings support  
403 immunisation programmes in the UK and several European countries, that advised the use of  
404 BA.1/ancestral mRNA bivalent booster doses in high risk individuals.

405 **FIGURE LEGENDS**

406

407 **Figure One: Study Flow Diagram**

408 (A) Inclusion and exclusion criteria in the cohort. The left panel describes the Spring-Summer  
409 monovalent booster analysis; of the 182 SARS-CoV-2 positive individuals, 78 were vaccinated  
410 with 4th dose monovalent mRNA vaccine, and 104 were vaccinated with 3rd dose monovalent  
411 mRNA vaccine. Of the 682 SARS-CoV-2 negative individuals admitted, 413 were vaccinated  
412 with 4th dose monovalent mRNA vaccine and 269 were vaccinated with 3rd dose monovalent  
413 mRNA vaccine. The right panel describes the Autumn-Winter bivalent booster analysis; of the  
414 152 SARS-CoV-2 positive individuals, 100 were vaccinated with 5th dose bivalent mRNA  
415 vaccine, and 52 were vaccinated with 4th dose monovalent mRNA vaccine. Of the 732 SARS-  
416 CoV-2 negative individuals admitted, 572 were vaccinated with 5th dose bivalent mRNA  
417 vaccine and 160 were vaccinated with 4th dose monovalent mRNA vaccine. (B) Study timeline

418 **Data Sharing**

419 The data used in this study are sensitive and cannot be made publicly available without  
420 breaching patient confidentiality rules. The data dictionary is therefore unavailable.

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

## 452 REFERENCES

- 453 1. Joint Committee on Vaccination and Immunisation (JCVI) statement on COVID-19  
454 vaccinations in 2022: 21 February 2022. [https://www.gov.uk/government/publications/joint-](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022)  
455 [committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022)  
456 [committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022)  
457 [21-february-2022](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022).
- 458 2. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety,  
459 immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given  
460 as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third  
461 dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. *Lancet*  
462 *Infect Dis.* 2022;22:1131–41.
- 463 3. Kirsebom FCM, Andrews N, Stowe J, Groves N, Chand M, Ramsay M, et al. Effectiveness of  
464 the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in  
465 England. *Lancet Reg Health – Eur.* 2022;23.
- 466 4. Luring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical  
467 severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and  
468 alpha SARS-CoV-2 variants in the United States: prospective observational study. *BMJ.*  
469 2022;376:e069761.
- 470 5. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9  
471 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study  
472 in Sweden. *Lancet Lond Engl.* 2022;399:814–23.
- 473 6. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of  
474 BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and  
475 severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ.* 2021;374:n1943.
- 476 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of  
477 COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in  
478 England. *Nat Med.* 2022;28:831–7.
- 479 8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-  
480 1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med.* 2022;28:1063–71.
- 481 9. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of  
482 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination  
483 and Delta Variant Predominance. *JAMA.* 2022;327:1032–41.
- 484 10. Lin D-Y, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, et al. Association of Primary and  
485 Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19  
486 Outcomes. *JAMA.* 2022;328:1415–26.



- 487 11. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-  
488 Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency  
489 Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of  
490 Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January  
491 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:255–63.
- 492 12. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of  
493 Protection against Mild and Severe Disease by Covid-19 Vaccines. *N Engl J Med.*  
494 2022;386:340–50.
- 495 13. Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine.  
496 [https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-](https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-originalomicron-booster-vaccine)  
497 [originalomicron-booster-vaccine](https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-originalomicron-booster-vaccine) [Internet]. [cited 2022 Nov 28]. Available from:  
498 <https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna>
- 499 14. Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines.  
500 [https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-](https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-originalomicron-booster-vaccine)  
501 [originalomicron-booster-vaccine](https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-originalomicron-booster-vaccine) [Internet]. [cited 2022 Nov 28]. Available from:  
502 [https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-](https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-originalomicron-booster-vaccine)  
503 [originalomicron-booster-vaccine](https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-originalomicron-booster-vaccine)
- 504 15. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A Bivalent Omicron-  
505 Containing Booster Vaccine against Covid-19. *N Engl J Med.* 2022;387:1279–91.
- 506 16. Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, et al. Immunogenicity  
507 of the BA.5 Bivalent mRNA Vaccine Boosters. *bioRxiv.* 2022;2022.10.24.513619.
- 508 17. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, et al. Antibody responses to  
509 Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot. *bioRxiv.* 2022;2022.10.22.513349.
- 510 18. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. mRNA bivalent booster  
511 enhances neutralization against BA.2.75.2 and BQ.1.1. *bioRxiv.* 2022;2022.10.31.514636.
- 512 19. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-  
513 2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent  
514 booster. *Nat Med.* 2022;1–1.
- 515 20. England Summary | Coronavirus (COVID-19) in the UK. <https://coronavirus.data.gov.uk>.  
516 2023.
- 517 21. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al.  
518 Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the  
519 Nordic countries [Internet]. *medRxiv*; 2023 [cited 2023 Jun 26]. p. 2023.01.19.23284764.  
520 Available from: <https://www.medrxiv.org/content/10.1101/2023.01.19.23284764v1>
- 521 22. SARS-CoV-2 variants of concern and variants under investigation in England: technical  
522 briefing 52. Available from:


- 523 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1152143/variant-technical-briefing-52-21-april-2023.pdf)  
524 [/1152143/variant-technical-briefing-52-21-april-2023.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1152143/variant-technical-briefing-52-21-april-2023.pdf)
- 525 23. Hyams C, Challen R, Begier E, Southern J, King J, Morley A, et al. Incidence of community  
526 acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A  
527 prospective cohort study. *Lancet Reg Health – Eur.* 2022;21.
- 528 24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data  
529 capture (REDCap)—A metadata-driven methodology and workflow process for providing  
530 translational research informatics support. *J Biomed Inform.* 2009;42:377–81.
- 531 25. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2  
532 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at  
533 least 80 years: a test-negative, case-control study. *Lancet Infect Dis.* 2021;21:1539–48.
- 534 26. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3  
535 September 2022. [https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-](https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022)  
536 [2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-](https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022)  
537 [programme-for-autumn-2022-update-15-august-2022.](https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022)
- 538 27. COVID-19 Vaccine Tracker | European Centre for Disease Prevention and Control [Internet].  
539 [cited 2023 Jun 29]. Available from: [https://qap.ecdc.europa.eu/public/extensions/COVID-](https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab)  
540 [19/vaccine-tracker.html#uptake-tab](https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab)
- 541 28. Greenland S. Quantifying biases in causal models: classical confounding vs collider-  
542 stratification bias. *Epidemiol Camb Mass.* 2003;14:300–6.
- 543 29. Lineages (raw) | COVID-19 Genomic Surveillance – Wellcome Sanger Institute.  
544 [https://covid19.sanger.ac.uk/lineages/raw?p\\_type=line&area=E06000023&lineageView=1&line](https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&lineages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2)  
545 [ages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C](https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&lineages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2)  
546 [0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2.](https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&lineages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2)
- 547 30. Wright DW, Harvey WT, Hughes J, Cox M, Peacock TP, Colquhoun R, et al. Tracking  
548 SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer. *Virus Evol.*  
549 2022;8:veac023.
- 550 31. Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron  
551 (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A  
552 prospective cohort study in Bristol, United Kingdom. *Lancet Reg Health - Eur.* 2023;25:100556.
- 553 32. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative  
554 analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron  
555 (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet.*  
556 2022;399:1303–12.
- 557 33. Cerqueira-Silva T, Oliveira V de A, Boaventura VS, Pescarini JM, Júnior JB, Machado TM,  
558 et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and  
559 CoronaVac vaccines: A population-based study. *Lancet Reg Health – Am.* 2022;6.

560 34. COVID-19 vaccine surveillance report: week 5.  
561 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1134076/vaccine-surveillance-report-week-5-2023.pdf)  
562 [/1134076/vaccine-surveillance-report-week-5-2023.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1134076/vaccine-surveillance-report-week-5-2023.pdf).

563 35. Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Effectiveness of  
564 BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults  
565 with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and  
566 July 2022: A prospective test negative case–control study. *Lancet Reg Health - Eur.*  
567 2023;25:100552.

568

**A**



**B**

